William Blair Investment Management LLC Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

William Blair Investment Management LLC grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 701.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 422,133 shares of the company's stock after acquiring an additional 369,471 shares during the quarter. William Blair Investment Management LLC owned 0.52% of IDEXX Laboratories worth $174,527,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in IDXX. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter worth about $30,000. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth $31,000. Kestra Investment Management LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth $38,000. Finally, Crews Bank & Trust acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $41,000. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX traded up $0.37 during trading on Friday, hitting $420.99. The company's stock had a trading volume of 706,610 shares, compared to its average volume of 550,561. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88. The company has a 50-day moving average of $437.30 and a 200-day moving average of $445.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market cap of $34.24 billion, a price-to-earnings ratio of 39.46, a P/E/G ratio of 3.41 and a beta of 1.39.

Remove Ads

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IDXX. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price objective on the stock. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, March 15th. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Finally, Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.